<!DOCTYPE html SYSTEM "about:legacy-compat"><html lang="en-US" data-colors-preset="contrast" data-primary-color="#307FFF"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="UTF-8"><meta name="robots" content="noindex">  <meta name="built-on" content="2024-01-01T12:25:13.3928426"><meta name="build-number" content="${buildNumber}">       <title>2天1板博瑞医药：BGM0504注射液处研发阶段，减重和2型糖尿病治疗适应症均仅获Ⅱ期临床试验伦理批件 | 20231016</title><script id="virtual-toc-data" type="application/json">[]</script><script id="topic-shortcuts" type="application/json"></script><link href="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.css" rel="stylesheet">   <link rel="apple-touch-icon" sizes="180x180" href="https://jetbrains.com/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="https://jetbrains.com/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="https://jetbrains.com/favicon-16x16.png"><link rel="manifest" href="https://jetbrains.com/site.webmanifest"><link rel="mask-icon" href="https://jetbrains.com/safari-pinned-tab.svg" color="#000000"><meta name="msapplication-TileColor" content="#000000"/><meta name="msapplication-TileImage" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-144x144.png"/><meta name="msapplication-square70x70logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-70x70.png"/><meta name="msapplication-square150x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-150x150.png"/><meta name="msapplication-wide310x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x150.png"/><meta name="msapplication-square310x310logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x310.png"/>  <meta name="image" content=""><!-- Open Graph --><meta property="og:title" content="2天1板博瑞医药：BGM0504注射液处研发阶段，减重和2型糖尿病治疗适应症均仅获Ⅱ期临床试验伦理批件 | 20231016"/><meta property="og:description" content=""/><meta property="og:image" content=""/><meta property="og:site_name" content="20231016 Help"/><meta property="og:type" content="website"/><meta property="og:locale" content="en_US"/><meta property="og:url" content="2406.html"/><!-- End Open Graph --><!-- Twitter Card --><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content=""><meta name="twitter:title" content="2天1板博瑞医药：BGM0504注射液处研发阶段，减重和2型糖尿病治疗适应症均仅获Ⅱ期临床试验伦理批件 | 20231016"><meta name="twitter:description" content=""><meta name="twitter:creator" content=""><meta name="twitter:image:src" content=""><!-- End Twitter Card --><!-- Schema.org WebPage --><script type="application/ld+json"> { "@context": "http://schema.org", "@type": "WebPage", "@id": "2406.html#webpage", "url": "2406.html", "name": "2天1板博瑞医药：BGM0504注射液处研发阶段，减重和2型糖尿病治疗适应症均仅获Ⅱ期临床试验伦理批件 | 20231016", "description": "", "image": "", "inLanguage":"en-US" }</script><!-- End Schema.org --><!-- Schema.org WebSite --><script type="application/ld+json"> { "@type": "WebSite", "@id": "/#website", "url": "/", "name": "20231016 Help" }</script><!-- End Schema.org --></head>      <body data-id="2406" data-main-title="2天1板博瑞医药：BGM0504注射液处研发阶段，减重和2型糖尿病治疗适应症均仅获Ⅱ期临床试验伦理批件" data-article-props="{&quot;seeAlsoStyle&quot;:&quot;links&quot;}"  data-template="article"  data-breadcrumbs=""  >   <div class="wrapper"><main class="panel _main"><header class="panel__header"><div class="container"><h3>20231016  Help</h3><div class="panel-trigger"></div></div></header><section class="panel__content"><div class="container"><article class="article" data-shortcut-switcher="inactive"><h1 data-toc="2406"   id="2406.md">2天1板博瑞医药：BGM0504注射液处研发阶段，减重和2型糖尿病治疗适应症均仅获Ⅱ期临床试验伦理批件</h1>  <p id="e85857ec_15"><span class="control" id="e85857ec_16">界面快报</span></p><p id="e85857ec_17"><span class="control" id="e85857ec_18">2023-10-16 10:02</span></p><p id="e85857ec_19"><span class="control" id="e85857ec_20">https://www.jiemian.com/article/10234396.html</span></p><p id="e85857ec_21">博瑞医药10月16日公告，公司股票于10月13日和10月16日连续两个交易日收盘价格涨幅偏离值累计达到30%，达成2天1板，根据《上海证券交易所科创板股票上市规则》《上海证券交易所交易规则》的有关规定，属于股票交易异常波动。</p><p id="e85857ec_22">公司控股子公司博瑞新创生物医药科技（无锡）有限公司自主研发的多肽类降糖药BGM0504注射液尚处于研发阶段。截至本公告披露日，减重和2型糖尿病治疗两项适应症均仅获得Ⅱ期临床试验伦理批件，其中2型糖尿病治疗的Ⅱ期临床已开始入组。待II期临床试验完成后，尚需经国家药品监督管理局（以下简称&ldquo;国家药监局&rdquo;）确认确证性临床试验方案，开展并完成III期临床研究，并经国家药监局审评、审批通过后方可生产上市。创新药研发周期长、研发投入大，各项临床研究的入组及研究方案实施等受到多种不确定因素影响，临床研究存在结果不及预期甚至临床研究失败的风险。公司特别提醒广大投资者，理性决策，注意防范投资风险。</p><div class="last-modified"> Last modified: 01 一月 2024</div><div data-feedback-placeholder="true"></div><div class="navigation-links _bottom">  <a class="navigation-links__prev" href="2407.html">金诚信现5707.52万元平价大宗交易</a>   <a class="navigation-links__next" href="2405.html">富恒新材：前三季度归母净利润同比预增37.99-47.85%，新增比亚迪等重要客户</a>  </div></article><div id="disqus_thread"></div></div></section></main></div>  <script src="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.js"></script></body></html>